OncBioMune Receives Patent for ProscaVax in Hong Kong

OncBioMune Pharmaceuticals (OTCQB:OBMP) obtained a patent in Hong Kong for ProscaVax, the company’s immunotherapeutic cancer vaccine.
As quotes in the press release:

The patent, titled, “Composition and Method for Treating Cancer,” protects ProscaVax in Hong Kong through January 8, 2032.
ProscaVax is a clinical-stage protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune’s intellectual property portfolio protecting ProscaVax and other technologies consists of 16 patents spanning approximately 50 countries worldwide.
“Prostate cancer is the third most common cancer in men in Hong Kong, accounting for approximately 11.3 percent of all newly diagnosed cancer cases in 2014,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “We will remain vigilant in protecting our assets as part of our quest to bring effective, safe therapeutics to people in need in Hong Kong and globally.”

Click here to read the full press release.

Source: www.marketwired.com